Figure 5 Identification of mucinous carcinoma

Slides:

Advertisements

Similar presentations

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Advertisements

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 New functional imaging techniques in lymphoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Intracranial targeting of high-grade gliomas

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Ex vivo synovial tissue culture viability

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 2 Haematoxylin and eosin staining

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Figure 4 Tracheal endoscopy in two patients

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 6 Image sequence demonstrating coronal cuts on MRI

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Palliative-care-referral patterns

Figure 3 Optical coherence tomography images of specialized intestinal

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Variations between planned and delivered doses of radiation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure Spinal cord imaging (A, B) Sagittal and axial T2-weighted cervical spine MRI demonstrating hyperintensities in the central gray matter of patient.

Preoperative T2-weighted magnetic resonance imaging (MRI) (sagittal view) shows disc herniation at the L4-L5 disc level (A) and axial view of MRI shows.

Serial biopsy samples taken from the patient in figs 1and 2, showing from left to right: acute myocarditis, healing myocarditis, dilated cardiomyopathy.

Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain and ×10 growth). Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain.

Cerebral magnetic resonance imaging of our patient performed at ∼7

Presentation transcript:

Figure 5 Identification of mucinous carcinoma Figure 5 | Identification of mucinous carcinoma. a | Sagittal and b | axial T2-weighted MRI scan of a patient with MC, which can be easily recognized owing to the distinctive mucinous high signal intensity on high-resolution MRI images. c,d | H&E-stained tumour (magnification ×1). This Figure emphasizes the need for careful mapping of tumour biopsy samples to preoperative imaging findings, in order to enable personalized medicine, based on initial biopsy. Arrows indicate the presence of mucinous regions of the tumour. Abbreviation: H&E, haematoxylin and eosin. Hugen, N. et al. (2015) Advances in the care of patients with mucinous colorectal cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.140